Slide 1: Investor presentation
Investor presentation Results for the 12-month period to 31 May 2023 12 September 2023 Connectivity that liberates healthcare
Slide 2: Disclaimer
Disclaimer The information contained in this confidential document (the “Presentation”) and any information disclosed in any oral presentation thereof has been prepared by Feedback plc (the “Company”). It has not been fully verified and is subject to material updating, revision and further amendment
Slide 3: Company overview
Company overview The frontline clinical technology company, well-positioned to capitalise on digital transformation underway in 1 healthcare in the UK and internationally Growing routes to market with Bleepa and CareLocker solutions delivering secure, compliant clinical workforce 2 tools and data ma
Slide 4: Operational highlights
Continued to focus on growth of high margin opportunities Sussex Integrated Care System community diagnostic centre pilot contract extension - providing increased revenue visibility Demonstrated an approximate 69% reduction in patient wait times compared to national targets Named as a supplier on G-
Slide 5: Financial highlights
Financial highlights 74% increase in revenue to £1.02m (all figures in £million) Revenue up 74% to £1.02m (2022: £0.59m) of which 74% Bleepa- Revenue & Sales EBITDA loss CareLocker. Includes £0.19m revenue for Sussex ICS related to 5-month period prior to contract signing (contract signed in Sep-22
Slide 6: Post period highlights
Numerous discussions underway both with local, regional and national NHS organisations, and strategic partners Post period Successfully granted an import license for Bleepa as a registered medical device in India highlights Appointment of India in-country Managing Director to drive the opportunity f
Slide 7: Product overview
r Product overview 4 FEEDBACKpIc
Slide 8: Bleepa
Key features • Common view of a patient’s data, securely accessible from any location, bridging the gap between Bleepa care settings and enabling seamless clinical pathway delivery • Asynchronous collaboration environment enabling efficient clinical input. • Only communication and workflow platform
Slide 9: CareLocker
Key features • Patient centric cloud architecture that bridges care settings and follows the patient across provider sites with unparalleled scalability, security and auditability. • Facilitates direct patient access to clinical results, as directed by the clinical team. What this means for care • C
Slide 10: Growth drivers
r Growth drivers 4 FEEDBACKpIc
Slide 11: Key value proposition by stakeholder
Key value proposition by stakeholder National - Connecting infrastructure across all care settings - Patient choice to attend any location and ability to leverage national specialist teams - Clinical services based around the patient rather than the care setting - Option of centralised national data
Slide 12: Our sales strategy – vertical and horizontal approach
Our sales strategy – vertical and horizontal approach NHS England – 2-3 depts Integrated care systems - 42 NHS trusts - 215 GPs/community – 6,495 Sales team Validation Conversion Scaling 12
Slide 13: NHS – contracts
Forecast modelling for Bleepa use(1) NHS – contracts Acute trusts Contract value: £107k/annum User base: ~1,022 clinicians Number of specialties: 7 Bleepa user Bleepa referral response times surveys and interviews (1): Sourced from health economic modelling findings by Unity Insights. For further in
Slide 14: NHS – contracts
NHS – contracts Acute trusts “Bleepa works very well for us as a 24-hour service in our emergency department, to supplement our stretched medical photography team…Any reduction in the time taken to review patients and help to improve their journey through the Contract value: £112k/annum hospital is
Slide 15: NHS – contracts
NHS – contracts Community diagnostic centres Contract Value: £338k/9months User base: 149 users and growing, 10 GP practices, 1 CDC and 1 hospital Number of specialties: 1 • Connects 10 GP practices with clinicians at 1 CDC and multi-disciplinary team in 1 hospital • Pioneering CDC site delivering e
Slide 16: Cross-provider care: Community diagnostic centres (CDCs)
Cross-provider care: Community diagnostic centres (CDCs) NHS England’s ambition is to bring diagnostic investigations closer to patients to reduce the post-COVID elective care backlog and improve the patient journey. This will enable patients to have tests such as imaging, bloods and ECGs in high-st
Slide 17: Cross-provider care: Integrated care systems (ICSs)
Cross-provider care: Integrated care systems (ICSs) An ICS is a partnership of organisations that come together to plan and deliver joined up health and care services 42 integrated care systems in England now established and operational with a corresponding integrated care board and integrated care
Slide 18: Cross-provider care: Route to breakeven
Cross-provider care: Route to breakeven • Regional CDC contracts with ICSs represent the clearest route to profitability • Estimated 6% market share required for breakeven – considered achievable • Equivalent to 10 individual CDC contracts (at assumed average pricing), or • Assuming each ICS contain
Slide 19: India – driving the opportunity for Bleepa
India – driving the opportunity for Bleepa Subsidiary now established in India and Managing Director for India Rohit Singh appointed – joins from UKIBC where, as a director, supported UK companies for 12 years to establish themselves in India Currently, limited value proposition in India for CareLoc
Slide 20: Imaging Engineering LLC
Imaging Engineering LLC • Leveraging legacy technology to generate additional revenues • License to develop products based on Cadran technology for X-ray image capture enabling repair and update to existing rather than new equipment • Large domestic market within the US, approx. 2,000 sites reaching
Slide 21: Recent significant activity in the NHS market
Recent significant activity in the NHS market Cancer target ICO NHS Lanarkshire CQC requirement for CDC initiative Hewitt Review changes ruling tools & care record • National £2.3bn • Removal of 2-week • Independent • Reprimand for NHS • Guidance for programme for wait standard in review of trust ov
Slide 22: Outlook
Outlook 1 Growing number of products, routes to markets and end customers Primary focus on cross-provider care delivery in the UK, predominantly in the cross-provider space, with higher 2 contract values and operational margins – estimated total addressable market of £96m 3 Focus on non-NHS markets
Slide 23: Appendices
r Appendices 4 FEEDBACKpIc
Slide 24: FY 2023 – Consolidated income statement
FY 2023 – Consolidated income statement FY 2023 FY 2022 £ £ Revenue 1,024,997 588,576 Cost of sales (84,276) (99,321) Gross profit 940,721 489,255 Other operating expenses (4,362,675) (3,002,489) Operating loss (3,421,954) (2,513,234) Net finance income 47,868 2,012 Loss before taxation (3,374,086)
Slide 25: FY 2023 – Consolidated balance sheet
FY 2023 – Consolidated balance sheet FY 2023 FY 2022 £ £ Property, plant and equipment 14,909 8,367 Intangible assets 3,710,946 3,288,811 Total non-current assets 3,725,855 3,297,178 Trade and other receivables 225,302 308,293 Corporation tax receivable 455,641 392,351 Cash and cash equivalents 7,31
Slide 26: FY 2023 – Consolidated cashflow statement
FY 2023 – Consolidated cashflow statement FY 2023 FY 2022 £ £ Cash flows from operating activities Loss before tax (3,374,086) (2,511,222) Adjustments for: Net finance income (47,868) (2,012) Depreciation and amortisation 809,333 552,931 Impairment of intangible assets 6,695 - Translation difference
Slide 27: ~£10bn annual TAM estimated in core target markets
~£10bn annual TAM estimated in core target markets Estimated total addressable market analysis - annual 1 2 3 4 5 6 7 8 9 North UK EU Private Private ABDM(2) – America National TB NHS trusts NHS - CDCs veterinary veterinary hospitals hospitals health TOTAL veterinary screening sector sector (UK) (In
Slide 28: Healthcare regulation – confidence in our products
Healthcare regulation – confidence in our products Data governance Medical device regulation Clinical risk • Governed by GDPR • UK: Medical Device • DCB 0129 – clinical risk and • NHS provider = data Directive – UKCA or CE safety standard, risk controller mark analysis and mitigation for • Feedback
Slide 29: Our credentials
Our credentials Standard What Why / what it demonstrates How UKCA Regulatory standard – confirming Allows the product to be sold for the intended Class 1 – self certification of conformance with MHRA that Bleepa displays digital purpose patient images at a standard Development and maintenance of a f
Slide 30: Feedback plc Board
Feedback plc Board Prof Rory Shaw, Non-executive Dr Thomas Oakley, Chief Executive Chairman: Ex senior NHS executive, Officer since February 2019, previously Medical Director of Healthcare UK, Dept Radiologist and Clinical Entrepreneur of International Trade, and consultant Fellow at NHS England. pu
Slide 31: Feedback Medical Ltd management team
Feedback Medical Ltd management team Dr Thomas Oakley, Chief Executive Officer since February 2019, previously Radiologist and Clinical Entrepreneur Fellow at NHS England. Anesh Patel, Chief Financial Mike Hayball, Chief Stephen McAteer, Chief Officer: Chartered Accountant Technology Officer: medica
Slide 32: Company history
• Contract extension with Sussex ICS for CDC programme 2023 • Establishment of Indian subsidiary and appointment of managing director for India Company history 2022 • Two Bleepa NHS contract wins • 12-month pilot extension of UK’s first end-to-end symptom-based CDC pathway • First international depl